

*Papait A, Silini AR, Gazouli M, Malvicini R, Muraca M, O'Driscoll L, Pacienza N, Toh WS, Yannarelli G, Ponsaerts P, Parolini O, Eissner G, Pozzobon M, Lim SK and Giebel B (2022), Perinatal derivatives: How to best validate their immunomodulatory functions. Front. Bioeng. Biotechnol. 10:981061. doi: 10.3389/fbioe.2022.981061*

<https://www.frontiersin.org/articles/10.3389/fbioe.2022.981061/full>

36312547; “Methods and criteria for validating the multimodal functions of perinatal derivatives when used in oncological and antimicrobial applications”

<https://pubmed.ncbi.nlm.nih.gov/36312547/>

36263355; „General consensus on multimodal functions and validation analysis of perinatal derivatives for regenerative medicine applications”

<https://pubmed.ncbi.nlm.nih.gov/36263355/>

35992360; “Perinatal derivatives: How to best characterize their multimodal functions in vitro. Part C: Inflammation, angiogenesis, and wound healing”

<https://pubmed.ncbi.nlm.nih.gov/35992360/>

33392174; “Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature”

<https://pubmed.ncbi.nlm.nih.gov/33392174/>